Congenital Disorders of Glycosylation: Advancing Diagnostics and Therapeutics Through Glycobiology

Looking Beyond Genes and Proteins

Genomics has transformed how we identify disease, and proteomics has expanded how we understand function. But in Congenital Disorders of Glycosylation (CDGs), neither tells the full story.

CDGs arise from defects in glycan synthesis and processing—pathways that regulate protein folding, stability, and signaling across nearly every cell type [1,2]. As a result, these disorders present with broad, often severe clinical phenotypes [3]. Despite advances in sequencing, many CDGs remain difficult to interpret at a functional level, underscoring a persistent gap between genetic findings and biological outcome [4].

This challenge reflects a broader issue in life science research: glycosylation is one of the most functionally important yet under-characterized post-translational modifications due to its structural complexity and context dependence [1].

Connecting Glycosylation to Disease Mechanism

Understanding CDGs requires more than identifying mutations—it requires determining how those mutations alter glycosylation within cells and tissues.

Changes in glycan structure can directly affect protein interactions, localization, and signaling [1]. Even subtle shifts in glycosylation can drive significant phenotypic consequences, particularly in systems where glycan-mediated regulation is critical. This is well established in areas like cancer and immunology, where glycosylation influences disease progression and therapeutic response [5].

To capture these effects, approaches that enable direct visualization and comparison of glycosylation in biological context are valuable. Lectin-based detection methods can allow glycan patterns to be mapped within intact tissues. The Glysite™ Explorer in situ PLA Glycan Detection Kit provides a look at protein glycosylation in a cell or tissue sample, but by visualizing when proteins and glycans are in proximity, Glysite Explorer adds protein-specific glycan analysis.

Advancing Diagnostics and Therapeutics Through Functional Glycosylation Analysis

Diagnosis remains a major challenge in CDGs. While genomic sequencing can identify candidate variants, linking these findings to functional outcomes is not always straightforward. Established methods such as transferrin analysis and mass spectrometry provide important information, but they do not fully resolve disease heterogeneity [4,7]. To achieve a more complete view of CDG biology, glycosylation must be incorporated directly into both diagnostic workflows and therapeutic development.

Glycan structures are highly sensitive to disease state, and changes in glycosylation like altered sialylation or fucosylation have demonstrated value in disease detection, patient stratification, and monitoring therapeutic response [8,9]. Because clinically relevant biomarkers like PD-1, PSA, and HER2 are glycoproteins, analyzing glycan composition adds a critical layer of specificity that protein-level measurements alone may miss [8]. In this context, experimental approaches that enable comparative glycan profiling across tissues or patient samples provide a valuable complement to existing methods. Lectin kits, glycan screening kits, and in situ detection strategies allow researchers to validate glycosylation changes within biological context, helping to connect molecular findings to functional outcomes [6]. This is particularly important in CDGs, where diagnostic ambiguity often stems from the challenge of linking genotype to phenotype [4]. For researchers incorporating glycan analysis into diagnostic development, lectin-based tools like Vector Laboratories’ purified lectins and novel lectin-based kits offer practical ways to profile and compare glycosylation patterns across samples within standard experimental workflows.

These same challenges extend into therapeutic development. Although progress has been made, most CDG treatments remain focused on symptom management. Targeted approaches like monosaccharide supplementation have demonstrated benefit in select subtypes, highlighting the therapeutic potential of correcting glycosylation defects [10,11]. However, advancing these strategies depends on the ability to measure whether interventions restore normal glycosylation. Without this functional readout, assessing efficacy and optimizing treatment remains difficult [10].

Glycosylation plays a direct role in modulating protein stability, signaling, and molecular interactions, meaning that restoring glycan structure has the potential to correct underlying disease mechanisms [1]. Realizing this potential requires tools that can track glycosylation changes in response to intervention and, critically, place those changes in biological context. Approaches that enable spatially resolved analysis of protein-glycan interactions are particularly valuable in this setting. By preserving tissue context, the protein-glycan co-localization provided by Glysite Explorer allows researchers to examine how glycosylation affects protein function at the cellular level, providing insight into treatment response that cannot be captured through bulk analysis alone.

Bringing Glycosylation into Focus

CDGs highlight a broader shift in biomedical research: understanding disease requires moving beyond genes and proteins to include glycosylation as a central regulatory layer.

What has changed is not the importance of glycosylation but the ability to study it. With more accessible tools for glycan detection, profiling, and spatial analysis, researchers can now integrate glycosylation into standard workflows with greater ease.

For CDG research, this shift enables a more complete view of disease biology—supporting improved diagnostics, deeper mechanistic understanding, and the development of more targeted therapies.

Read the following articles for more information on how studying protein glycosylation unlocks avenues of understanding, and how the right tools make that possible:

• The Overlooked PTM: Making Glycosylation More Accessible to Researchers
• Revisiting Colon Cancer Metastasis Through a Glycobiology Lens
• Glycosylation in the Alzheimer’s Brain: Visualizing New Paths to Diagnosis and Therapy
• Advancing Colorectal Cancer Research with Biomarker-Driven Tools
• A New Focus for Breast Cancer: Protein Glycosylation’s Emerging Role

References

1. Varki, A., Cummings, R. D., Esko, J. D., et al. (2017). Essentials of Glycobiology (3rd ed.). Cold Spring Harbor Laboratory Press.
2. Stanley, P., & Cummings, R. D. (2022). Structures common to different glycans. In A. Varki et al. (Eds.), Essentials of Glycobiology (4th ed.). Cold Spring Harbor Laboratory Press.
3. Ferreira, C. R., Altassan, R., Marques-Da-Silva, D., Francisco, R., Jaeken, J., & Morava, E. (2018). Recognizable phenotypes in CDG. Journal of inherited metabolic disease, 41(3), 541–553. https://doi.org/10.1007/s10545-018-0156-5
4. Chang, I. J., He, M., & Lam, C. T. (2018). Congenital disorders of glycosylation. Annals of Translational Medicine, 6(24), 477. https://doi.org/10.21037/atm.2018.10.45
5. Pinho, S. S., & Reis, C. A. (2015). Glycosylation in cancer: Mechanisms and clinical implications. Nature Reviews Cancer, 15(9), 540–555. https://doi.org/10.1038/nrc3982
6. Hirabayashi, J., Yamada, M., Kuno, A., & Tateno, H. (2013). Lectin microarrays: Concept, principle and applications. Chemical Society Reviews, 42(10), 4443–4458. https://doi.org/10.1039/c3cs35419a
7. Jaeken, J., & Matthijs, G. (2015). Congenital disorders of glycosylation: A rapidly expanding disease family. Annual Review of Genomics and Human Genetics, 16, 405–434. https://doi.org/10.1146/annurev-genom-090314-045954
8. Kailemia, M. J., Park, D., & Lebrilla, C. B. (2017). Glycans and glycoproteins as specific biomarkers for cancer. Analytical and Bioanalytical Chemistry, 409, 395–410. https://doi.org/10.1007/s00216-016-9880-6
9. Reiding, K. R., Bondt, A., Franc, V., & Wuhrer, M. (2019). Human plasma N-glycosylation as analyzed by mass spectrometry. FEBS Journal, 286(18), 3604–3620. https://doi.org/10.1111/febs.14975
10. Cechova, A., Altassan, R., Borgel, D., Bruneel, A., Lafitte, F., Seta, N., & Vuillaumier-Barrot, S. (2022). Congenital disorders of glycosylation: From bench to bedside. European Journal of Medical Genetics, 65(1), 104379. https://doi.org/10.1016/j.ejmg.2021.104379
11. Ondruskova, N., Honzik, T., Vondrackova, A., Tesarova, M., & Hansikova, H. (2021). Congenital disorders of glycosylation: Still “hot” in 2020. Biochimica et Biophysica Acta (BBA) – General Subjects, 1865(1), 129751.